M
Morphic Therapeutic
Biotech & Life Sciences · Waltham, United States · Founded 2015 · IPO 2019
Biotechnology company developing a new generation of oral integrin therapies MoreLess
Morphic Therapeutic is at the forefront of developing a new generation of oral integrin drugs, leveraging decades of expertise and a unique integrin discovery platform. The company aims to revolutionize the treatment landscape for patients suffering from serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer.
Morphic operates in the biopharmaceutical industry, targeting a specialized market of patients with chronic and severe health conditions. The company's business model revolves around the research, development, and commercialization of oral integrin drugs. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved drugs.
Morphic's integrin platform is supported by significant partnerships with major healthcare investors and organizations, which provide both financial backing and strategic guidance. The company is led by a team of experienced scientists and industry leaders, including founder Timothy Springer, PhD, and Chief Scientific Officer Shelia Violette, PhD.
The company’s innovative approach focuses on making integrin-targeting therapies more accessible and effective by developing oral formulations, which could offer a more convenient alternative to current treatments that often require injections or infusions.
Keywords: oral integrin drugs, chronic diseases, autoimmune, cardiovascular, fibrosis, cancer, biopharmaceutical, integrin platform, partnerships, commercialization.
Company overview
Morphic Therapeutic company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Waltham, United States
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 26.8
Valuation & funding
Morphic Therapeutic funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2024 | $3.2B | $3.2B | Eli Lilly | ↗ |
| POST IPO EQUITYOther financing | Mar 2023 | $100M | — | Undisclosed | ↗ |
| IPOOther financing | Jun 2019 | — | $429M | Undisclosed | — |
| SERIES BOther financing | Sep 2018 | $80M | $320M | Omega Funds · Invus · Novo Holdings · EcoR1 Capital | ↗ |
| SERIES AOther financing | Jun 2016 | $52M | $206M | ShangPharma · Abbvie Biotech Ventures · SR One · Polaris Partners | — |
| SEEDOther financing | Jan 2016 | Undisclosed | — | ||
| SPINOUTOther financing | Jan 2015 | Harvard University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $330K | 0% | −$178M | -53816.7% |
| 2025 | $330K | +32% | −$178M | -53816.7% |
| 2024 | $250K | -52% | −$178M | -71038% |
| 2023 | $521K | -99.3% | −$178M | -34087.3% |
| 2022 | $71M | +257.7% | −$63M | -89.5% |
| 2021 | $20M | -56% | −$96M | -484% |
| 2020 | $45M | — | −$47M | -105% |
Growth signals
Morphic Therapeutic website traffic
Latest recorded traffic for Morphic Therapeutic is 400 monthly website visits, down 91.5% over the last three months. Morphic Therapeutic's team declined 77.7% over the past year.
Comparisons
Morphic Therapeutic compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Morphic Therapeutic's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Morphic Therapeutic has talent and traffic
team presence
In the news
Latest news about Morphic Therapeutic
Recent press, funding announcements, and product moves mentioning Morphic Therapeutic — open to read from the original sources.
Market sentiment
What the market is saying about Morphic Therapeutic
An AI-synthesized read of the highest-engagement posts about Morphic Therapeutic on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Morphic Therapeutic’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.